Pharmacokinetics of bevacizumab in haemodialysis

Nephrol Dial Transplant. 2007 Mar;22(3):975. doi: 10.1093/ndt/gfl664. Epub 2006 Nov 8.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / analysis
  • Angiogenesis Inhibitors / pharmacokinetics*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / analysis
  • Antibodies, Monoclonal / pharmacokinetics*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Dialysis Solutions / chemistry*
  • Drosophila Proteins
  • Enzyme-Linked Immunosorbent Assay
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Receptors, Cell Surface
  • Renal Dialysis / methods*
  • Renal Insufficiency / metabolism*
  • Renal Insufficiency / therapy
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dialysis Solutions
  • Drosophila Proteins
  • Receptors, Cell Surface
  • Vascular Endothelial Growth Factor A
  • gustatory receptor, Drosophila
  • Bevacizumab